Evidence map›Paper›PMID 25562317›Full record

ArticlePLoS medicine2015

Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data.

Daniel M Weinberger, Keith P Klugman, Claudia A Steiner, Lone Simonsen, Cécile Viboud

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 4 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 4 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Trial
  6. Trial
  7. Article
  8. The Effectiveness of Nirsevimab on Antibiotic Use in Children Using Target Trial Emulation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. RSV: an overview of infection in adults.Pneumonia (Nathan Qld.) · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Daniel M WeinbergerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America; Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Keith P KlugmanDepartment of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
Claudia A SteinerHealthcare Cost and Utilization Project, Agency for Healthcare Research and Quality, Rockville, Maryland, United States of America.
Lone SimonsenDivision of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America; Department of Global Health, George Washington University, Washington, District of Columbia, United States of America.
Cécile ViboudDivision of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America.
Agency for Healthcare Research and Quality · USEmory University · USFogarty International Center · USNational Institutes of Health · USYale University · US

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Denise Esserman · 2002 to 2026
$37.9M
Yale University Clinical and Translational Science Award ProgramUL1TR000142 · NCATS · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2012 to 2015
$31.8M
NCATS NIH HHS UL1 TR000142NIA NIH HHS P30 AG021342NIA NIH HHS P30AG021342
6 · The paper itself

Abstract

backgroundThe importance of bacterial infections following respiratory syncytial virus (RSV) remains unclear. We evaluated whether variations in RSV epidemic timing and magnitude are associated with variations in pneumococcal disease epidemics and whether changes in pneumococcal disease following the introduction of seven-valent pneumococcal conjugate vaccine (PCV7) were associated with changes in the rate of hospitalizations coded as RSV. METHODS AND

findingsWe used data from the State Inpatient Databases (Agency for Healthcare Research and Quality), including >700,000 RSV hospitalizations and >16,000 pneumococcal pneumonia hospitalizations in 36 states (1992/1993-2008/2009). Harmonic regression was used to estimate the timing of the average seasonal peak of RSV, pneumococcal pneumonia, and pneumococcal septicemia. We then estimated the association between the incidence of pneumococcal disease in children and the activity of RSV and influenza (where there is a well-established association) using Poisson regression models that controlled for shared seasonal variations. Finally, we estimated changes in the rate of hospitalizations coded as RSV following the introduction of PCV7. RSV and pneumococcal pneumonia shared a distinctive spatiotemporal pattern (correlation of peak timing: ρ = 0.70, 95% CI: 0.45, 0.84). RSV was associated with a significant increase in the incidence of pneumococcal pneumonia in children aged <1 y (attributable percent [AP]: 20.3%, 95% CI: 17.4%, 25.1%) and among children aged 1-2 y (AP: 10.1%, 95% CI: 7.6%, 13.9%). Influenza was also associated with an increase in pneumococcal pneumonia among children aged 1-2 y (AP: 3.2%, 95% CI: 1.7%, 4.7%). Finally, we observed a significant decline in RSV-coded hospitalizations in children aged <1 y following PCV7 introduction (-18.0%, 95% CI: -22.6%, -13.1%, for 2004/2005-2008/2009 versus 1997/1998-1999/2000). This study used aggregated hospitalization data, and studies with individual-level, laboratory-confirmed data could help to confirm these findings.

conclusionsThese analyses provide evidence for an interaction between RSV and pneumococcal pneumonia. Future work should evaluate whether treatment for secondary bacterial infections could be considered for pneumonia cases even if a child tests positive for RSV. Please see later in the article for the Editors' Summary.

Indexed as

Heptavalent Pneumococcal Conjugate VaccineHospitalizationHumansIncidenceInfantInfant, NewbornPneumonia, PneumococcalPrevalenceRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsSeasonsUnited StatesHeptavalent Pneumococcal Conjugate Vaccine

Identifiers

PMID25562317
PMCPMC4285401
OpenAlexW1987106455

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.